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Background: During 2007–2010, the National Health and Nutrition Examination Survey (NHANES) conducted a
spirometry component which obtained pre-bronchodilator pulmonary lung function data on a nationally
representative sample of US adults aged 6–79 years and post-bronchodilator pulmonary lung function data for the
subset of adults with airflow limitation. The goals of this study were to 1) compute prevalence estimates of chronic
obstructive pulmonary disease (COPD) using pre-bronchodilator and post-bronchodilator spirometry measurements
and fixed ratio and lower limit of normal (LLN) diagnostic criteria and 2) examine the potential impact of
nonresponse on the estimates.
Methods: This analysis was limited to those aged 40–79 years who were eligible for NHANES pre-bronchodilator
spirometry (n=7,104). Examinees with likely airflow limitation were further eligible for post-bronchodilator testing
(n=1,110). Persons were classified as having COPD based on FEV1/FVC < 70% (fixed ratio) or FEV1/FVC < lower limit
of normal (LLN) based on person’s age, sex, height, and race/ethnicity. Those without spirometry but self-reporting
both daytime supplemental oxygen therapy plus emphysema and/or current chronic bronchitis were also classified
as having COPD. The final analytic samples for pre-bronchodilator and post-bronchodilator analyses were 77.1%
(n=5,477) and 50.8% (n=564) of those eligible, respectively. To account for non-response, NHANES examination
weights were adjusted to the eligible pre-bronchodilator and post-bronchodilator subpopulations.
Results: In 2007–2010, using the fixed ratio criterion and pre-bronchodilator test results, COPD prevalence was 20.9%
(SE 1.1) among US adults aged 40–79 years. Applying the same criterion to post-bronchodilator test results, prevalence
was 14.0% (SE 1.0). Using the LLN criterion and pre-bronchodilator test results, the COPD prevalence was 15.4% (SE 0.8),
while applying the same criterion to post-bronchodilator test results, prevalence was 10.2% (SE 0.8).
Conclusions: The overall COPD prevalence among US adults aged 40–79 years varied from 10.2% to 20.9% based on
whether pre- or post-bronchodilator values were used and which diagnostic criterion (fixed ratio or LLN) was applied.
The overall prevalence decreased by approximately 33% when airflow limitation was based on post-bronchodilator as
compared to pre-bronchodilator spirometry, regardless of which diagnostic criterion was used.
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According to the Global Initiative for Chronic Obstruct-
ive Lung Disease (GOLD), COPD is a preventable and
treatable disease characterized by airflow limitation that
is not fully reversible [1]. Spirometry measurements can
be used to define COPD, specifically the forced expira-
tory volume in the first second (FEV1), and the FEV1 to
forced vital capacity (FVC) ratio [1-3]. Accordingly, the
American Thoracic Society / European Respiratory Soci-
ety (ATS/ERS) standards for the diagnosis and manage-
ment of patients with COPD state that spirometry
should be performed in all patients suspected of COPD
and is necessary for diagnosis, assessment of disease se-
verity, and monitoring disease progression [3].
Recent estimates based on self-reported data show that
15 million Americans aged 18 years and older have been
diagnosed with COPD [4]. Estimating the prevalence of
COPD can, however, be challenging and may vary based
on the diagnostic method (e.g. self-report or spirometry),
the criteria used for defining COPD (e.g. GOLD, ATS/
ERS), and the age group analyzed (e.g., 18 years and older
or 40 years and older). Estimates will also vary if pre-
bronchodilator or post-bronchodilator spirometry results
are used with the GOLD guidelines advocating the use of
post-bronchodilator spirometry [1] while the ATS/ERS
guidelines support the use of pre-bronchodilator spirom-
etry [5]. The GOLD criteria with the fixed cutoff may be
simpler to use in daily clinical practice [6,7], however,
studies suggest that it overestimates disease burden in the
elderly [8,9]. While the ATS/ERS guidelines may be better
suited to capture age-related decline in pulmonary func-
tion, their use is more computationally intensive and re-
quires appropriate, population-based, reference equations
for the interpretation of pulmonary function tests [5].
During 2007–2010, the U.S. National Health and Nutri-
tion Examination Survey (NHANES) conducted a spirom-
etry component which obtained pre-bronchodilator and
post-bronchodilator pulmonary lung function data on sur-
vey participants 6–79 years of age. Data on respiratory
symptoms and diseases were also collected. These data
offer a unique opportunity to examine multiple approaches
to estimating the prevalence of COPD in a large nationally
representative sample.
The main objectives of this study were 1) to estimate
the prevalence of COPD in the United States based on
pre-bronchodilator and post-bronchodilator spirometry
measurements and according to the operational defini-
tions in the two major published guidelines: ATS/ERS
and GOLD [1,5,10] and 2) to examine the potential im-
pact of nonresponse on the estimated prevalence.
Methods
NHANES is a cross-sectional survey of the civilian,
non-institutionalized U.S. population conducted by theNational Center for Health Statistics of the Centers for
Disease Control and Prevention [11]. Data were collected
via household interviews and standardized physical exami-
nations in specially equipped mobile examination centers
(MEC). The NHANES survey samples are selected through
a complex, multistage, probability design. Each annual
sample is nationally representative, however NHANES data
are publicly released for 2-year survey periods to protect
confidentiality and increase statistical reliability. The 2007–
10 NHANES survey cycles oversampled major U.S. demo-
graphic subgroups including Hispanic and non-Hispanic
black persons, low income white persons, and persons
aged 80 years and older. The procedures to select the sam-
ple and conduct the interview and examination have been
specified elsewhere [12]. Informed consent was obtained
from all participants and the National Center for Health
Statistics Research Ethics Review Board approved the
protocol.
This study was based on analysis of NHANES 2007–
2008 and 2009–2010 data for participants 40–79 years.
During 2007–2010, 9,985 persons aged 40–79 years were
eligible for the survey, 7296 (73%) were interviewed and
7104 (71%) attended the NHANES MEC exam and were
invited to participate in the spirometry component, which
included pre-bronchodilator and post-bronchodilator lung
function assessment. Of the 7104 eligible, 649 participants
were excluded from spirometry for safety reasons: current
chest pain or pain with forceful expiration, currently tak-
ing daytime supplemental oxygen, had recent surgery of
the eye, chest or the abdomen; had a recent heart attack,
stroke, tuberculosis exposure, hemoptysis, a history of de-
tached retina or pneumothorax. An additional 632 partici-
pants did not receive spirometry due to limited time
available in the MEC (n=337), subject refusals (n=113), or
some other reason (n=182). In total, 5,823 adults aged 40–
79, or 82% of those eligible, received spirometry.
Of these 5,823 examinees, 1110 were eligible for the
bronchodilator study based on pre-bronchodilator spir-
ometry values that indicated possible airflow obstruc-
tion per ATS/ERS or GOLD criteria. Possible airflow
obstruction, per the ATS/ERS criterion, was defined as
a pre-bronchodilator FEV1/FVC ratio less than the
lower limit of normal (LLN) representing the lower 5th
percentile based on person’s age, sex, height, and race/
ethnicity [5]. LLN values were determined using norma-
tive reference equations developed from NHANES III
data by Hankinson et al. [13]. Possible airflow obstruc-
tion, per the GOLD criterion, was a pre-bronchodilator
FEV1/FVC ratio less than 70%. Of the 1110 who qualified
for post-bronchodilator testing, 238 did not perform the
post-bronchodilator test due to subject refusals or limited
time available in the MEC. An additional 305 were ex-
cluded due to safety reasons which included active cardio-
vascular disease (uncontrolled blood pressure, irregular
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arrhythmia, having an implanted defibrillator, or history of
congenital heart disease) or taking certain prescription
medications (a monoamine oxidase inhibitor, an anticon-
vulsant, a tricyclic antidepressant plus current treatment
for cardiac disease, or potassium lowering drugs). Exam-
inees were also excluded from bronchodilator administra-
tion if they had already recently taken a β2-adrenergic
bronchodilator to avoid exceeding FDA recommended
doses, or if they had had a previous adverse reaction to al-
buterol. Also, women who were pregnant or breastfeeding
were excluded. In total, 543 adults aged 40–79 did not re-
ceive the bronchodilator test while 567, or 51% of those eli-
gible, received the test (Figure 1).
Among those who received the pre-bronchodilator
spirometry test (n=5823) and the post-bronchodilator
spirometry test (n=567), 94% and 100%, respectively, had
acceptable quality data for analysis. Acceptable quality
was defined as either meeting or exceeding the ATS data
quality standard [14] of 3 acceptable and 2 reproducible
spirometric curves with 2 observed values for both FEV1
and FVC within 150 ml (87% of all tests), or a lesser
standard where there were 2 curves where FEV1 values
were within 200 ml, and FVC values were within 200 ml
(7% of all tests). The final pre-bronchodilator and post-
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Figure 1 Flow diagram of the study population.Spirometry testing
Spirometry testing was performed in accordance with rec-
ommendations of the ATS [14] using Ohio 822/827 dry-
rolling seal volume spirometers with in-line biological fil-
ters (A-M Systems PFT Filter Kit B) to minimize infection
risks. These were the same spirometers that were used in
the NHANES III (1988–1994) spirometry testing. Spirom-
etry was almost always performed in the standing position
unless the participant had a physical limitation. Partici-
pants were coached on proper head and chin position and
used a nose clip to prevent air leaks during testing. They
were then instructed to perform a series of maximal
forced expiratory maneuvers using standard technique.
Testing for an individual continued until he/she was able
to achieve a reproducible spirogram, or until a maximum
of eight spirometry curves had been obtained, or until the
participant could not continue. The overall goal was for
the participant to achieve three acceptable exhalation ma-
neuvers by ATS criteria in which the two highest values
for the FVC and the FEV1 (each taken from an acceptable
forced expiratory maneuver) showed minimal variability:
i.e. the two largest FVC values taken from 2 acceptable
curves should agree within 150 ml, and similarly for the
two largest values for the FEV1 [15].
If a participant was selected for bronchodilator testing,
the MEC physician explained the testing procedure,
obtained informed consent and administered albuterol.d Spirometry 
 [n=5823]
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grams of albuterol sulfate each, taken one minute apart,
from a PROAIR HFA™ inhalation aerosol, meter-dosed in-
haler (MDI) and through an AeroChamber MAX™ spacer.
Spirometric testing was then repeated. Spirometric testing
procedures for the pre-bronchodilator exam and the post-
bronchodilator exam were identical. For detailed descrip-
tions of the testing protocol and quality control procedures,
refer to the NHANES 2009–10 Respiratory Health Spirom-
etry Procedure manual [15].
Using both pre- and post-bronchodilator spirometry
values, participants were defined as having evidence of
COPD based on either the fixed ratio (FEV1/FVC <
0.70) or LLN (FEV1/FVC < LLN) criteria.
Other assessments of COPD
Prior to receiving the initial pre-bronchodilator spirometry
exam, participants were asked if they currently had a
breathing problem that required the use of supplemental
oxygen during the daytime. Persons on daytime supple-
mental oxygen who also reported health care provider- di-
agnosed emphysema or current chronic bronchitis were
additionally classified as having evidence of COPD.COPD severity
Severity was calculated for both pre- and post-
bronchodilator test results. To ensure reliability of esti-
mates (relative standard errors ≤ 30%) and to maximize
comparability between diagnostic criteria, severity stages
were combined into three categories. Using the fixed ra-
tio criterion, participants were categorized as having
mild (FEV1≥80% predicted), moderate (50%≤FEV1<80%
predicted), or severe/very severe (FEV1<50% predicted)
disease per the GOLD guidelines [1]. Using the LLN cri-
terion, participants were categorized as having mild
(FEV1>70% predicted), moderate and moderately se-
vere (50%≤FEV1≤70% predicted), or severe/very severe
(FEV1<50% predicted) disease per the ATS/ERS guide-
lines [5].
Percent of predicted FEV1 was defined as the observed
FEV1 value divided by the predicted FEV1 value estimated
for a person of the same age, gender, race/ethnicity, and
height using race-specific reference equations for the U.S.
population [13]. The U.S. population predicted values are
available online and the method used to derive them de-
scribed in the literature [13]. Reference values are available
for non-Hispanic white, non-Hispanic black, and Mexican
Americans. In this study, for the “other” race category, we
applied a correction factor of 0.88 to the corresponding
values for non-Hispanic whites, which has been previously
published as an adjustment factor for Asian participants
[16]. For the “other Hispanic” group, we applied the pre-
dicted values for Mexican Americans.Participant’s height was measured using a standard
protocol in the NHANES Anthropometry exam compo-
nent. Data on sixteen persons with missing measured
height values were imputed using a single imputation lin-
ear regression model with the following predictors: forced
vital capacity, gender, ethnicity, and self-reported height.
Other measurements
Demographic data were collected during the household
interview. Age was categorized as 40–59 and 60–79
years. Self-reported race and Hispanic origin were cate-
gorized as non-Hispanic white, non-Hispanic black,
Mexican American, other Hispanic, and “other”. Partici-
pants in the “other Hispanic” and “other” categories are
included in overall estimates, but results for these
groups are not reported separately.
Statistical methods
Statistical analyses were performed using STATA™ ver-
sion 12.1 (StataCorp, College Station, TX). Examination
sample weights were used to account for differential
probabilities of selection and the complex NHANES
sample design and to obtain prevalence estimates and
their standard errors that were representative of the
non-institutionalized U.S. population ages 40–79 years.
Age adjustment was carried out by the direct method
using the year 2000 Census Bureau projections for the
U.S. civilian, non-institutionalized population using 2
age groups: 40–59 and 60–79. Standard errors were esti-
mated by Taylor series linearization. Chi-square tests
were performed to examine the association between co-
variates and exam completion status. All estimates
presented have a relative standard error ≤30% [17].
For the estimates based solely on pre-bronchodilator
data, the examination weights of those persons defined
as responders (n=5532) were adjusted, using response
propensity scores, to equal the examination weight totals
of those eligible for pre-bronchodilator testing (n=7104).
Responders to pre-bronchodilator spirometry were de-
fined as those having a complete, acceptable quality,
pre-bronchodilator spirometry exam or reporting daily
supplemental oxygen use plus self-reported, health care
provider COPD diagnosis (ever had emphysema or
current chronic bronchitis). Twenty-three percent of
those eligible for pre-bronchodilator spirometry did not
satisfy either of these requirements and were classified
as non-responders to pre-bronchodilator spirometry. To
compensate for the potential impact of nonresponse to
pre-bronchodilator spirometry testing on the prevalence
estimates, we adjusted the original examination sampling
weights for responders using the inverse of the
respondent's predicted response probability (propensity
score) obtained from a logistic regression model as the
examination weight adjustment factor [18-20]. As there
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respondents in a number of covariates including age, race,
and self-reported COPD diagnosis, the logistic model used
for all the reweighting adjustments included the demo-
graphic and outcome-related covariates of age, race, gender,
self-reported COPD diagnosis, number of years smoked,
and self-reported current asthma status as the independent
variables with response/nonresponse to pre-bronchodilator
spirometry testing as the binary dependent outcome.
For the estimates obtained using pre- and post-
bronchodilator data, we employed a 2-stage re-weighting
adjustment to account for nonresponse at the level of both
pre-bronchodilator and post-bronchodilator spirometry. In
the first stage, the examination weights of the post-
bronchodilator responders (n=564) were adjusted, using
the inverse of the modeled response propensity scores, to
equal the examination weight totals of those eligible for
post-bronchodilator testing (n=1110). Responders for post-
bronchodilator spirometry were defined as those having a
complete, acceptable quality, post-bronchodilator spirom-
etry exam while non-responders to post-bronchodilator
spirometry were those without. In the second stage, this
reweighted post-bronchodilator responder group (n=564)
was combined with those who completed baseline spirom-
etry and had spirometric results showing no indication of
lung obstruction (n=4367) and those who reported daily
supplemental oxygen use plus self-reported, health care
provider COPD diagnosis (n=55). The weights for this
combined group (n=4986), now representing the full com-
plement of post-bronchodilator outcomes, were adjusted
using the inverse of the modeled response propensity
scores to equal the examination weight totals of all those
eligible for spirometry (n=7104).
To assess the reliability of the estimates obtained using
the 2-stage, pre- and post-bronchodilator reweighting, we
also multiply imputed the missing post-bronchodilator
data to account for post-bronchodilator nonresponse then
applied the adjusted examination weights used for the esti-
mates based solely on pre-bronchodilator data to account
for pre-bronchodilator nonresponse. Post-bronchodilator
FEV1 and FVC values were multiply imputed using a
chained equation model with each resulting predicted
FEV1 value divided by its corresponding predicted FVC
value to generate a predicted post-bronchodilator FEV1/
FVC ratio. The chained equation model to predict post-
bronchodilator FEV1 and FVC values included the follow-
ing predictors: impaired basic functional activities, had
current respiratory illness, eosinophil count, mean FENO
measure (exhaled nitric oxide), C-reactive protein level,
number of years smoked, cotinine level, number of
pack-years smoked, pre-bronchodilator FVC value, pre-
bronchodilator FEV1 value, prior diagnosis of asthma,
current smoker, age, race, gender, height, self-reported
COPD diagnosis (emphysema or current bronchitis),chronic cough, chronic phlegm, atopy (allergic response)
indicator, number of wheezing/whistling attacks in past
year, low level of education (less than 9th grade), and high
level of education (college graduate or above). As this was
a predictive model and not an explanatory model, we were
not concerned with multicollinearity or its effect on the in-
dividual coefficient estimates. Rather, our goal was max-
imally informed predictions so, for this reason, we included
a number of similar predictors in the model such as current
smoker, number of years smoked, number of pack-years
smoked, and cotinine level. Forty imputations of the miss-
ing post-bronchodilator data were used to produce preva-
lence estimates as this was the number determined to
minimize preventable statistical power falloff [21].Results
Characteristics of persons eligible for pre- and post-
bronchodilator spirometry are summarized in Table 1.
The overall exam completion rate for pre-bronchodilator
spirometry was 77.1 percent. 1,627 eligible individuals
were excluded from the analysis due to safety reasons, not
having quality spirometry results or other non-response.
Spirometry completion rates were higher among 40–59
year olds (81.4%) than 60–79 year olds (72.0%); p<0.001,
progressively higher with more education (Less than 12th
grade, 69.2%; HS grad/equivalent, 78.1%; Some college or
AA degree, 80.9%; College graduate or above, 84.1%;
p<0.001), and higher for those with no self-reported
COPD diagnosis (yes, 55.2%; No, 78.5%; p<0.001). There
were also significant differences in spirometry completion
rates with respect to race/ethnicity (Non-Hispanic white,
80.4%; Non-Hispanic black, 72.8%; Mexican-American,
75.9%; p<0.001).
Of the 1,110 persons eligible for the post-bronchodilator
spirometry, 564 persons had complete, acceptable quality
bronchodilator results (50.8% response rate). Mirroring the
baseline spirometry completion rates, post-bronchodilator
completion rates were higher among 40–59 year olds
(58.2%) than 60–79 years olds (45.6%); p<0.001, progres-
sively higher with more education (Less than 12th grade,
44.4%; HS grad/equivalent, 46.8%; Some college or AA de-
gree, 56.6%; College graduate or above, 59.8%; p<0.001),
and higher for those with no self-reported COPD diagnosis
(yes, 30.2%; No, 53.2.5%; p<0.001). In contrast to the base-
line spirometry, more men completed the post-
bronchodilator exam than women (54.7% vs. 44.8%;
p<0.001) and there were also significant differences in
post-bronchodilator completion rates by smoking status
(Current smoker, 45.2%; Past smoker, 50.7%; Never
smoked, 57.7%; p<.05).
Prevalence estimates of COPD based on the fixed ratio
criterion are presented in Table 2. When applying the
fixed ratio criterion to pre-bronchodilator spirometry
Table 1 Distribution of persons eligible for spirometry and examined
Pre-bronchodilator spirometry Post-bronchodilator spirometry













Total 7,104 100.0 77.1 1,110 100.0 50.8
Gender 0.086 0.001
Male 3,495 49.2 78.0 675 60.8 54.7
Female 3,609 50.8 76.3 435 39.2 44.8
Race and ethnic origin <.001 0.092
Non-Hispanic white 3,362 47.3 80.4 705 63.5 53.2
Non-Hispanic black 1,437 20.2 72.8 195 17.6 42.1
Mexican American 1,217 17.1 75.9 99 8.9 52.5
Age <.001 <.001
40–59 3,839 54.0 81.4 455 41.0 58.2
60–79 3,265 46.0 72.0 655 59.0 45.6
Education <.001 <.001
Less than 12th grade 2,270 32.0 69.2 331 29.9 44.4
HS Grad/GED/
Equivalent
1,655 23.3 78.1 301 27.2 46.8
Some College or AA
degree
1,773 25.0 80.9 272 24.6 56.6
College Graduate or
above
1,395 19.7 84.1 204 18.4 59.8
Smoking status 0.373 0.022
Current smoker 1,479 20.8 75.5 378 34.1 45.2
Past smoker 2,110 29.7 77.9 414 37.3 50.7




No 6,680 94.0 78.5 994 89.6 53.2
Yes 424 6.0 55.2 116 10.5 30.2
aNumber of persons aged 40–79 years who attended the NHANES MEC exam, 2007-10.
bPercent of those eligible with a complete pre-bronchodilator spirometry examination and acceptable quality exam results by ATS/ERS Criteria or had a minimum
of 2 curves where FEV1 values were within 200 ml and FVC values were within 200 ml. This combination is denoted in the data as SPXNSTAT=1.
cSubset of those persons with a complete, acceptable quality pre-bronchodilator spirometry examination that have results suggestive of airflow obstruction (pre-
bronchodilator FEV1/FVC < .7 or < LLN)
dPercent of those eligible with a complete post-bronchodilator spirometry examination and acceptable quality exam results (minimum 2 curves where FEV1
values were within 200 ml and FVC values were within 200 ml). This combination is denoted in the data as SPXBSTAT=1.
eChi-square values computed for differences between examined and non-examined (eligible less examined) persons.
fSelf-reported, health care provider diagnosed COPD assessed by an affirmative response to either ever having emphysema or still having chronic bronchitis.
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40–79 years was 20.3% (SE=1.1) when using the ori-
ginal examination weights and 20.9% (SE=1.1) with
non-response adjusted weights. The prevalence esti-
mates for demographic subgroups were similar when
using the original weights and the nonresponse ad-
justed weights (0.1-0.6% differences). Regardless of
which survey weights were used, about 11% of adults
aged 40–79 years had mild disease, 8% had moderate,
and 1% had severe/very severe COPD.When applying the fixed ratio criterion to post-
bronchodilator spirometry values, the overall preva-
lence of COPD was 8.3% (SE=0.7) using the original
examination weights. After adjusting for nonresponse by
imputation or reweighting, the post-bronchodilator esti-
mate using the fixed ratio was 13.7% (SE=0.8) and 14.0%
(SE=1.0), respectively. Estimates were similar for demo-
graphic subgroups and disease severity regardless of which
non-response adjustment approach was used, that is im-
putation or reweighting. Specifically, about 7.5% were mild
Table 2 COPD prevalence (%)* in major demographic subgroups using the fixed ratio criterion (FEV1/FVC<0.70)
Fixed ratio criterion (FEV1/FVC<0.70)
Estimates based on pre-
bronchodilator spirometry dataa










Pre-BR and Post-BR weights
adjusted for non-response
(n = 4986)
Post-BR missing data imputed then
Pre-BR weights adjusted
for non-response (n = 5532)
Overall 20.3 (1.1) 20.9 (1.1) 8.3 (0.7) 14.0 (1.0) 13.7 (0.8)
Stage I (Mild)c 10.9 (0.7) 11.0 (0.7) 5.0 (0.6) 7.9 (0.8) 7.2 (0.5)
Stage II (Moderate)c 7.8 (0.6) 8.0 (0.6) 2.4 (0.2) 4.7 (0.5) 5.0 (0.4)
Stage III and IV
(Severe/Very Severe)c
1.1 (0.2) 1.2 (0.2) 0.3 (0.1) 0.7 (0.2) 0.8 (0.2)
Age
40–59 15.4 (1.2) 15.6 (1.2) 6.2 (0.7) 9.4 (1.0) 9.2 (0.9)
60–79 30.7 (1.3) 31.2 (1.3) 13.3 (1.1) 23.0 (1.7) 22.6 (1.2)
Gender
Male 24.1 (1.2) 24.8 (1.3) 11.4 (0.9) 17.4 (1.2) 17.4 (1.0)
Female 16.7 (1.3) 17.3 (1.3) 5.4 (0.6) 10.8 (1.3) 10.4 (0.8)
Race and ethnic origin
Non-Hispanic white 22.5 (1.2) 22.9 (1.2) 9.5 (0.8) 15.0 (1.1) 14.9 (0.9)
Non-Hispanic black 17.4 (1.3) 18.0 (1.4) 6.9 (0.9) 14.1 (2.0) 12.8 (1.3)
Mexican-American 10.1 (.7) 10.4 (0.7) 2.7 (0.6) 5.4 (1.1) 5.8 (0.8)
*Standard errors of the estimates are given in parentheses.
Adults Aged 40–79 Years: NHANES 2007-10.
aEstimates based on pre-bronchodilator included those who completed the pre-bronchodilator test plus those persons excluded from pre-BR spirometry who had
a medical diagnosis of emphysema or chronic bronchitis plus used daytime supplemental oxygen therapy.
bEstimates based on pre and post-bronchodilator included those who completed the pre-bronchodilator test and were not selected for the post-bronchodilator
test (no disease), plus those persons who completed the post-bronchodilator test, plus those persons excluded from pre-BR spirometry who had a medical
diagnosis of emphysema or chronic bronchitis plus used daytime supplemental oxygen therapy. The 546 persons who did not complete the post-bronchodilator
test are included in the numerator of the imputed estimates as their post-bronchodilator data was multiply imputed.
cSpirometric classification used the following cutoffs per GOLD specifications: Mild (Stage 1): PPFEV1 ≥ 80%, Moderate (Stage 2): 50% ≤PPFEV1 < 80%, Severe and
Very severe (Stages 3 and 4): PPFEV1 < 50%.
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COPD.
Prevalence estimates of COPD based on the LLN cri-
terion are presented in Table 3. Based on the LLN criter-
ion and pre-bronchodilator spirometry values, the
overall prevalence of COPD was 15.0% (SE=0.8) using
the original examination weights and 15.4% (SE=0.8)
using the adjusted weights. Estimates were similar for
demographic subgroups and disease severity when using
the original or adjusted weights. About 10% had mild, a
little over 3% had moderate or moderately severe, and
about 1% had severe/very severe disease. Prevalence was
about 14-17% among all gender, age, and race/ethnic
groups except among Mexican-American adults who
had a prevalence of 8.7%.
Applying the LLN criterion to post-bronchodilator spir-
ometry, the overall prevalence estimates for COPD using
the original examination weights was 6.1% (SE=0.5). By
comparison, after multiple imputation or after reweighting,
the post-bronchodilator estimates using the LLN ratio were
10.2% (SE=0.7) and 10.2% (SE=0.8), respectively. Estimates
were similar for demographic subgroups and by diseaseseverity regardless of which non-response approach was
used, that is either multiple imputation or reweighting ad-
justment. Specifically, about 6.5 to 7% had mild disease,
about 2% had moderate or moderately severe, and about
0.5% had severe/very severe disease.
Discussion
Spirometry can be used to define COPD yet currently
established guidelines (e.g., ATS/ERS and GOLD) differ in
their recommendation for using spirometric measure-
ments to do so. Specifically, the GOLD guidelines recom-
mend using post-bronchodilator FEV1/FVC <0.70 and
ATS/ERS recommends pre-bronchodilator FEV1/FVC <
LLN. Applying both of these criteria to the 2007–2010
NHANES spirometry data, we found the prevalence of
COPD in the U.S. for individuals aged 40 to 79 years to
be 14.0% using the fixed ratio criterion with post-
bronchodilator spirometry (GOLD) and 15.4% using the
LLN criterion with pre-bronchodilator spirometry (ATS/
ERS). Currently, no other published post-bronchodilator
COPD prevalence estimates exist for the overall U.S.
population. A similar study, conducted outside the U.S.,
Table 3 COPD prevalence (%)* in major demographic subgroups using the LLN criterion (FEV1/FVC<LLN)
LLN Criterion (FEV1/FVC<LLN)
Estimates based on pre-
bronchodilator spirometry dataa










Pre-BR and Post-BR weights
adjusted for non-response
(n = 4986)
Post-BR missing data imputed then
Pre-BR weights adjusted for
non-response (n = 5532)
Overall 15.0 (0.8) 15.4 (0.8) 6.1 (0.5) 10.2 (0.8) 10.2 (0.6)
Mildc 10.2 (0.5) 10.2 (0.5) 4.4 (0.5) 7.2 (0.7) 6.5 (0.5)
Moderate/
Moderately Severec
3.3 (0.3) 3.4 (0.3) 0.8 (0.2) 1.7 (0.4) 2.2 (0.3)
Severe/Very Severec 1.1 (0.2) 1.2 (0.2) 0.3 (0.1) 0.5 (0.1) 0.8 (0.2)
Age
40–59 14.0 (1.1) 14.2 (1.1) 5.4 (0.6) 8.3 (1.0) 8.1 (0.8)
60–79 17.2 (0.8) 17.8 (.8) 7.7 (0.7) 13.8 (1.3) 14.4 (0.9)
Gender
Male 16.0 (1.0) 16.5 (1.1) 8.0 (0.7) 12.2 (1.0) 12.0 (0.9)
Female 14.1 (1.0) 14.4 (1.0) 4.3 (0.6) 8.4 (1.1) 8.6 (0.7)
Race and ethnic origin
Non-Hispanic white 16.3 (0.9) 16.7 (0.9) 6.8 (0.6) 10.7 (0.9) 11.0 (0.8)
Non-Hispanic black 14.8 (1.2) 15.3 (1.3) 5.8 (0.8) 11.7 (1.8) 10.8 (1.2)
Mexican-American 8.4 (0.7) 8.7 (.7) 1.8 (0.4) 3.6 (0.8) 4.2 (0.7)
*Standard errors of the estimates are given in parentheses.
Adults Aged 40–79 Years: NHANES 2007-10.
aEstimates based on pre-bronchodilator included those who completed the pre-bronchodilator test plus those persons excluded from pre-BR spirometry who had
a medical diagnosis of emphysema or chronic bronchitis plus used daytime supplemental oxygen therapy.
bEstimates based on pre and post-bronchodilator included those who completed the pre-bronchodilator test and were not selected for the post-bronchodilator
test (no disease), plus those persons who completed the post-bronchodilator test, plus those persons excluded from pre-BR spirometry who had a medical
diagnosis of emphysema or chronic bronchitis plus used daytime supplemental oxygen therapy. The 546 persons who did not complete the post-bronchodilator
test are included in the numerator of the imputed estimates as their post-bronchodilator data was multiply imputed.
cSpirometric classification used the following cutoffs per ATS/ERS specifications: Mild: PPFEV1 > 70%, Moderate/Moderately severe: 50% ≤PPFEV1 <= 70%, Severe
and Very Severe: PPFEV1 < 50%.
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etry data in an aged 40+ population was the PLATINO
study which found a 14.3% pooled prevalence across
five Latin American cities [22]. This is comparable to
the estimated U.S. prevalence of 14.0% we found using
fixed ratio, post-bronchodilator spirometry data in a
population ages 40 to 79 years.
Examination of the differences between using pre-
bronchodilator and post-bronchodilator data revealed a
reduction in COPD prevalence after bronchodilation,
relative to before bronchodilation, of 33% using the
fixed ratio criterion (pre-bronchodilator 21% vs. post-
bronchodilator 14%) and 34% for the LLN criterion
(pre-bronchodilator 15% vs. post-bronchodilator 10%).
This puts our pre- to post-bronchodilator reduction es-
timates at the high end, but within, the 25-35% range of
reductions in prevalence found in a number of other
studies [23-26]. This finding further strengthens the
growing body of evidence that COPD prevalence rates
computed using post-bronchodilator spirometry are
likely to be 25-35% lower than those computed using
pre-bronchodilator spirometry.Comparing results obtained based on currently
established guidelines, the overall COPD prevalence rates
using the GOLD post-bronchodilator and ATS/ERS pre-
bronchodilator criteria were somewhat similar at 14.0%
(SE=1.0) and 15.4% (SE=0.8), respectively. COPD preva-
lence according to disease severity stage was somewhat
similar, as well (overlapping confidence intervals), with
some of the residual point estimate differences explained,
in part, by the different cut-points used by the GOLD and
ATS/ERS systems to define COPD severity stages. For ex-
ample, the GOLD criteria define mild disease as greater
than or equal to a percent of predicted FEV1 (PPFEV1)
of ≥0.8, whereas ATS/ERS defines mild COPD with a
slightly larger range of PPFEV1 ≥0.7. As a result, the calcu-
lated ATS/ERS prevalence estimate for mild COPD (pre-
bronchodilator) was 10.2% (SE=0.5), compared to the 7.9%
(SE=0.8) rate for the GOLD criteria (post-bronchodilator).
Conversely, for moderate disease, the GOLD moderate
stage has a slightly wider range of values (.5 ≤ PPFEV1 < .8)
than the ATS/ERS moderate and moderately severe stage
specifications (.5 ≤ PPFEV1 ≤ .7), hence the prevalence of
moderate COPD severity was expectedly higher for the
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compared to (pre-bronchodilator) ATS/ERS criteria (3.4%,
SE=0.3). When the severity is equivalent for both diagnostic
criteria, as is the case with severe and very severe disease
(PPFEV1 < .5), the prevalence estimates were again similar
with GOLD producing an estimate of 0.7% (SE=0.2) and
ATS/ERS producing 1.2% (SE=0.2).
Using the fixed ratio criterion with post-bronchodilator
spirometry led to greater variability than when using the
LLN criterion with pre-bronchodilator spirometry when
estimating the COPD prevalence by demographic sub-
groups. Most notably, COPD prevalence was 14.2% among
those aged 40–59 years and 17.8% among those aged 60–
79 years using LLN and pre-bronchodilator data com-
pared to the 9.4% prevalence for 40–59 year olds and 23%
prevalence for 60–79 year olds using the fixed ratio and
post-bronchodilator data. This appears to be a common
finding, as other studies have shown that using the fixed
ratio to define airflow limitation will result in more fre-
quent diagnosis of COPD in the elderly [8,9], and less fre-
quent diagnosis among those younger than 45 years [27].
On the other hand, some criticisms of the LLN include
the lack of longitudinal studies validating the use of the
LLN and the argument that its use may underestimate
the true burden of disease.
In this study, disease classification and subsequent
prevalence estimates are based solely on spirometric as-
sessments with the exception of self-reported supplemen-
tal oxygen use. Using spirometry alone to classify disease
is consistent with the methods used in other population
based studies, however, this represents a simplified and
measurable case definition in a research study setting, as
opposed to an actual disease diagnosis in a clinical setting
[28] and could potentially lead to disease misdiagnosis. To
reduce potential misdiagnosis, the most recent GOLD
committee recommendations have included evaluating
symptoms and risk factors, in addition to evaluating spiro-
metric results, when clinically diagnosing COPD [1]. The
fielding of our study preceded these recommendations
and, as a result, it was not possible to evaluate all the
symptoms and risk factors from our survey content. As
daytime supplemental oxygen use together with self-
reported, health care provider-diagnosed emphysema or
current chronic bronchitis is thought to be indicative of
the disease with a high degree of certainty, even in the ab-
sence of a spirometric assessment, persons with these
characteristics were also classified as having COPD. Since
they were excluded from the exam due to supplemental
oxygen use, and subsequently had no spirometric data, the
disease stage for these persons could not be determined.
However, given their supplemental oxygen use, it is likely
they are in one of the more severe stages of disease. These
supplemental classification criteria, not based on spirom-
etry measurements, applied to a small number of cases(55) and increased the overall, strictly spirometry-based
prevalence rates only by a small amount: about one half of
one percentage point.
A limitation of our study was that primarily due to safety
exclusions and time available for exams, we had nearly
50% nonresponse for post-bronchodilator testing. This
resulted in a significant portion of potentially positive dis-
ease cases being missing due to nonresponse. To account
for this missing data, estimates were produced, and com-
pared, using two different approaches: multiple imputation
of the missing data and re-weighting of those cases with
valid spirometry data. Although we applied different strat-
egies to account for non-response, the presented estimates
may still be an underestimation as some of the eligible par-
ticipants were excluded from the bronchodilator portion of
the exam due to the recent use of a prescribed broncho-
dilator. Recent bronchodilator use was not accounted for
in the nonresponse adjustment.
Beyond missing data, there were also other limitations
in the study. Persons with no race designation on the pub-
lic use file (other) were assigned predicted pulmonary
values which were 88% of the corresponding predicted
pulmonary values for whites. This adjustment factor was
originally derived for Asians and, since some participants
in this “other” group may be other than Asian, this correc-
tion factor may cause some misclassification of COPD se-
verity stage. Similarly, application of predicted values
derived from Hispanics of Mexican origin to Hispanics of
non-Mexican origin could possibly cause some misclassifi-
cation of COPD severity stage due to differences in smok-
ing habits, culture, and ancestry. The more severe stages
of COPD may have been further underreported by limit-
ing our analyses to the use of acceptable quality curves
(grades of A, B, or C). Curve quality was determined using
both within-maneuver evaluations (no cough during first
second, no extra breaths, etc.) and between-maneuver
evaluations (number of acceptable spirograms, ATS-
defined reproducibility criteria) [14]. As the likelihood of
producing reproducible spirometric measurements may
decrease with increasing severity of lung disease, the ex-
clusion of nonreproducible tests could potentially and se-
lectively exclude a higher proportion of persons with
obstructive airways disease [29,30]. We expected that this
exclusion due to lack of test reproducibility would have a
negligible impact on our results. The number of persons
in the poor quality spirometry curve group was relatively
small (349 persons out of 7104 eligible, or 5%) and the
6.3% rate of self-reported, health care provider-diagnosed
COPD (affirmative response to either having emphysema
or current bronchitis) for these 349 persons was only mar-
ginally higher than the 5.2% rate found for the entire
group eligible for spirometry (n=7104).
Finally, the most recent GOLD guidelines recommend
the use of either the Modified British Medical Research
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ment Test (CAT) for assessing symptoms in patients
with COPD [1]. Although NHANES does collect some
respiratory symptom data, it was not a close match to
the GOLD specifications. ATS guidance regarding
COPD symptom criteria is even less specific than the
GOLD criteria. We therefore limited the scope of our
study primarily to spirometric definitions of COPD to
make valid comparisons between ATS and GOLD cri-
teria. It should be noted, however, that the multiple im-
putation models to predict FEV1 and FVC values
included available symptom information to generate
maximally informed prediction equations.
In conclusion, the overall prevalence of COPD among
U.S. adults aged 40–79 years ranged from 10.2% to 20.9%
based on whether pre- or post-bronchodilator values were
used and which diagnostic criterion (fixed ratio or LLN)
was applied. These estimates provide the first U.S. national
estimates of impaired lung function evidence of COPD
using both pre- and post-bronchodilator spirometry mea-
surements. Using the GOLD recommended combination of
a fixed ratio criterion and post-bronchodilator spirometry
resulted in an overall COPD prevalence estimate of ap-
proximately 14% while using the ATS/ERS recommended
combination of LLN criterion and pre-bronchodilator spir-
ometry resulted in an overall prevalence of about 15%. The
overall prevalence decreased by approximately 33% when
airflow limitation was based on post-bronchodilator testing
as compared to pre-bronchodilator spirometry, regardless
of which diagnostic criterion was used. Due to the large
percentage of missing post-bronchodilator data, the
NHANES post-bronchodilator data required adjustment
for nonresponse but either method of adjustment, mul-
tiple imputation or reweighting, appeared to provide
similar results. Nonresponse adjustment of the pre-
bronchodilator data did not lead to significant differ-
ences in computed prevalence estimates.
Conclusions
The overall prevalence of COPD among US adults aged
40–79 years varied from 10.2% to 20.9% based on whether
pre- or post-bronchodilator values were used and which
diagnostic criterion (fixed ratio or LLN) was applied. The
overall prevalence decreased by approximately 33% when
airflow limitation was based on post-bronchodilator as
compared to pre-bronchodilator spirometry, regardless of
which diagnostic criterion was used.
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